Multidrug resistance in cancer: role of ATP–dependent transporters
The DOI matches its Crossref record; 167 of the 168 references it cites were found in a registry or an index.
Abstract
Chemotherapeutics are the most effective treatment for metastatic tumours. However, the ability of cancer cells to become simultaneously resistant to different drugs--a trait known as multidrug resistance--remains a significant impediment to successful chemotherapy. Three decades of multidrug-resistance research have identified a myriad of ways in which cancer cells can elude chemotherapy, and it has become apparent that resistance exists against every effective drug, even our newest agents. Therefore, the ability to predict and circumvent drug resistance is likely to improve chemotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A common mechanism of multidrug resistance consists in the overexpression of cancer drug–extruding ABC transporters in malignant cells (58).”
From SRC kinase drives multidrug resistance induced by KRAS-G12C inhibition (2024) · cites this paper as [58]
In the citing paper
“Prior exposure to taxanes during treatment of mCRPC can induce resistance mechanisms, including upregulation of efflux pumps or mutations in tubulin, that may compromise the efficacy of microtubule inhibitor-based ADCs246,247.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [247]
Citations
Cites
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104 · cited 1×
“But why can some patients be cured by these approaches and others respond transiently or incompletely? Host and tumour genetic alterations, epigenetic changes and tumour environment all seem to contribute to the complex story of cancer drug resistanc”
BackgroundOverexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
A multidrug resistance transporter from human MCF-7 breast cancer cells
Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., & Ross, D. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.26.15665 · Cited by 2,322 · cited 1×
“cgi?l=9429">ABCG2 — also known as MXR (mitoxantrone-resistance gene), BCRP (breast cancer resistance protein) or ABC-P (ABC transporter in placenta”
BackgroundNormalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184 · cited 1×
“Recent studies have emphasized the importance of the tumour vasculature and an appropriate pressure gradient for adequate drug delivery to the tumou”
BackgroundBIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059 · cited 1×
“asp?DrugCode=A%2D10166&DrugName=PACLITAXEL%2CSEMI%2DSYNTHETIC+INTRAVEN%2E&DrugType=1">paclitaxel”
Self-citationChen, C.-J., Chin, J. E., Ueda, K., Clark, D. P., Pastan, I., Gottesman, M. M., & Roninson, I. B. (1986) · Cell · doi:10.1016/0092-8674(86)90595-7 · Cited by 1,898
Self-citationA family of drug transporters: the multidrug resistance-associated proteins
Borst, P., Evers, R., Kool, M., & Wijnholds, J. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.16.1295 · Cited by 1,751 · cited 1×
“The discovery of MRP1 stimulated a genomic search for homologues, leading to the discovery of eight additional members of the ABCC subfamily of transporters, of which six have been studied in some detai”
BackgroundThe Human ATP-Binding Cassette (ABC) Transporter Superfamily
Dean, M., Rzhetsky, A., & Allikmets, R. (2001) · Genome Research · doi:10.1101/gr.184901 · Cited by 1,748
Research works printed but not linked: 3
- Solary, E. et al. Sufficient levels of quinine in the serum circumvent the multidrug resistance of the human leukemic cell line K562/ADM. Cancer 68, 1714–1719 (1991). · doi:10.1002/1097-0142(19911015)68:8<1714::aid-cncr2820680811>3.0.co;2-2
- Abraham, J. et al. A phase I study of the novel P-glycoprotein (PGP) antagonist, XR9576 in combination with vinorelbine. Proc. Am. Soc. Clin. Oncol. 20, 287 (2001).
- Fedeli, L. et al. Pharmacokinetics of vincristine in cancer patients treated with nifedipine. Cancer 64, 1805–1811 (1989). · doi:10.1002/1097-0142(19891101)64:9<1805::aid-cncr2820640908>3.0.co;2-d
Cited by
Items 701–800 of 1,041
Regulation of miR-19 to Breast Cancer Chemoresistance Through Targeting PTEN
Liang, Z., Li, Y., Huang, K., Wagar, N., & Shim, H. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0570-y · Cited by 124
“The multidrug resistance (MDR) refers to the ability of tumor cells to resist several unrelated drugs after exposure to a single chemotherapy drug (1).”
BackgroundHall, M. D., Brimacombe, K. R., Varonka, M. S., Pluchino, K. M., Monda, J. K., Li, J., Walsh, M. J., Boxer, M. B., Warren, T. H., Fales, H. M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2006047 · Cited by 116
“(Z)-N-(naphthalen-1-yl)-2-(2-oxoindolin-3-ylidene)hydrazinecarbothioamide (2) was prepared by reacting isatin with 4-(1′-napthyl)-3-thiosemicarbazide (Trans World, Rockville, MD), yield 24%.”
BackgroundMethodSelf-citationSphingolipids: Key Regulators of Apoptosis and Pivotal Players in Cancer Drug Resistance
Giussani, P., Tringali, C., Riboni, L., Viani, P., & Venerando, B. (2014) · International Journal of Molecular Sciences · doi:10.3390/ijms15034356 · Cited by 132
“A large range of molecular mechanisms are implicated in drug resistance: these include increased rates of drug efflux, alterations in drug metabolism, mutations of drug targets [1–4], the presence of cancer stem cells [5], the activation of survival signalling pathways and the inactivation of downstream”
BackgroundMei, L., Zhu, G., Qiu, L., Wu, C. S., Chen, H., Liang, H., Cansız, S., Lv, Y., Zhang, X., & Tan, W. (2015) · Nano Research · doi:10.1007/s12274-015-0841-8 · Cited by 118
Curcumin as a Modulator of P-Glycoprotein in Cancer: Challenges and Perspectives
Lopes-Rodrigues, V., Sousa, E., & Vasconcelos, M. (2016) · Pharmaceuticals · doi:10.3390/ph9040071 · Cited by 115
“In some cases, cells are cross-resistant to several unrelated (structurally and mechanistically different) drugs, a phenomenon known as multidrug resistance (MDR) [1,2].”
BackgroundGlycolysis-induced drug resistance in tumors—A response to danger signals?
Marcucci, F., & Rumio, C. (2021) · Neoplasia · doi:10.1016/j.neo.2020.12.009 · Cited by 124
Liu, Q., Wu, B., Li, M., Huang, Y., & Li, L. (2021) · Advanced Science · doi:10.1002/advs.202103911 · Cited by 120
Pharmacophore-based discovery of ligands for drug transporters
Chang, C. K., Ekins, S., Bahadduri, P. M., & Swaan, P. W. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.006 · Cited by 124
“P-gp also represents an attractive target for multidrug resistance reversal agents because co-administration of P-gp inhibitors has been observed to increase the oral bioavailability of P-gp substrate drugs [87] and several compounds are in clinical studies [88].”
BackgroundZhang, H., Zhang, X., Wu, X., Li, W., Su, P., Cheng, H., Xiang, L., Gao, P., & Zhou, G. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.03.039 · Cited by 125
Multidrug Resistance Through the Spectacle of P-Glycoprotein
Goda, K., Bacsó, Z., & Szabo, G. (2009) · Current Cancer Drug Targets · doi:10.2174/156800909788166493 · Cited by 124
Singh, H., Du, J., & Yi, T. (2016) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2016.1228663 · Cited by 115
“Despite many efforts, multi drug resistance is still considered as a major drawback in chemotherapy of cancer which has been the subject of exhaustive experiments (Gottesman et al. 2002).”
BackgroundNeggers, J. E., Kwanten, B., Dierckx, T., Noguchi, H., Voet, A., Bral, L., Minner, K., Massant, B., Kint, N., Delforge, M., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02349-8 · Cited by 112
Collins, D. M., Conlon, N. T., Kannan, S., Verma, C. S., Eli, L. D., Lalani, A. S., & Crown, J. P. (2019) · Cancers · doi:10.3390/cancers11060737 · Cited by 125
“P-glycoprotein (P-gp; multidrug resistance protein 1 [MDR1]/ATP-binding cassette sub-family B member 1 [ABCB1]) is a drug efflux pump with a physiological role in the pharmacokinetics and pharmacodynamics of drugs, and it is a major mediator of tumor multidrug resistance [127].”
Overcoming Drug Resistance and Treating Advanced Prostate Cancer
Semenas, J., Allegrucci, C., Boorjian, S. A., Mongan, N. P., & Persson, J. L. (2012) · Current Drug Targets · doi:10.2174/138945012802429615 · Cited by 125
“Various additional taxane resistance mechanisms have been described including upregulation of membrane-bound efflux proteins such as ATP-binding cassette (ABC) transporters P-glycoprotein (Pgp)/MDR1 (ABCB1), MDR2 (ABCB4), or MRP1 (ABCC1) [75], direct mutation-driven alterations of the drug target such as tubulin [76]…”
BackgroundPape, V. F. S., Tóth, S., Füredi, A., Szebényi, K., Lovrics, A., Szabó, P. T., Wiese, M., & Szakács, G. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.03.078 · Cited by 123
“single cytotoxic agent show cross-resistance to str uctu ally and mechanistically unrelated drugs [3].”
Targeting Membrane Lipid a Potential Cancer Cure?
Tan, L. T., Chan, K., Pusparajah, P., Lee, W.-L., Chuah, L., Khan, T. M., Lee, L., & Goh, B. H. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00012 · Cited by 114
“Increasing evidence has demonstrated various mechanisms by which cancer cells may acquire resistance such as drug-detoxifying mechanisms, expression of one or more energydependent transporters that extrude anticancer agent from the cells before interaction with intracellular targets take place, or acquiring the abilit…”
BackgroundXiao, W., Liu, L., Guo, X., Wang, Y., Zhao, J., & Zhou, S. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.8b04163 · Cited by 114
Hu, J., Yuan, I. J., Mirshahidi, S., Simental, A., Lee, S. C., & Yuan, X. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041950 · Cited by 130
Abdul‐Ghani, R., Serra, V., Győrffy, B., Jürchott, K., Solf, A., Dietel, M., & Schäfer, R. (2005) · Oncogene · doi:10.1038/sj.onc.1209201 · Cited by 122
“Other mechanisms of drug resistance involve alterations in the apoptotic response, activation of DNA repair or stimulation of detoxifying systems such as the exocytotic pathway for reducing intracellular drug concentration (Stavrovskaya, 2000; Gottesman, 2002; Gottesman et al., 2002).”
BackgroundSilencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice
Shi, H., Li, D., Zhang, J., Wang, Y., Li, Y., Zhang, H., Wang, X., Mu, B., Wang, W., Ma, Y., et al. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01562.x · Cited by 121
Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling
Martins‐Neves, S. R., Paiva‐Oliveira, D. I., Wijers‐Koster, P. M., Abrunhosa, A., Ribeiro, C., Bovée, J. V. M. G., Cleton-Jansen, A., & Gomes, C. M. F. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.11.013 · Cited by 126
Trastuzumab decorated TPGS-g-chitosan nanoparticles for targeted breast cancer therapy
Mehata, A. K., Bharti, S., Singh, P., Viswanadh, M. K., Kumari, L., Agrawal, P., Singh, S. K., Koch, B., & Muthu, M. S. (2018) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2018.10.007 · Cited by 113
Notch1 regulates the expression of the multidrug resistance gene ABCC1/MRP1 in cultured cancer cells
Cho, S., Lu, M., He, X., Ee, P.-L. R., Bhat, U., Schneider, E., Miele, L., & Beck, W. T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1019452108 · Cited by 113
Multiple drugbinding sites on the R482G isoform of the ABCG2 transporter
Clark, R., Kerr, I. D., & Callaghan, R. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706904 · Cited by 127
“Reduction of anticancer drug accumulation is a primary or initial mechanism in the development of a resistant phenotype in cancer (Gottesman et al., 2002; Leonard et al., 2003).”
BackgroundThe bad seed: Cancer stem cells in tumor development and resistance
Koren, E., & Fuchs, Y. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.06.006 · Cited by 119
Fluorescent carbon dots from mono- and polysaccharides: synthesis, properties and applications
Hill, S. A., & Galán, M. C. (2017) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.13.67 · Cited by 112
Zhou, J., Liu, M., Aneja, R., Chandra, R., Lage, H., & Joshi, H. C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1779 · Cited by 112
“compounds have not yet been successful, in large part because of their confounded pharmacokinetic interaction with anticancer drugs and their notorious side effects (3).”
BackgroundInfluentialPorro, A., Haber, M., Diolaiti, D., Iraci, N., Henderson, M., Gherardi, S., Valli, E., Munoz, M. A., Xue, C., Flemming, C., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.078584 · Cited by 110
Inhibition of P-Glycoprotein-Mediated Paclitaxel Resistance by Reversibly Linked Quinine Homodimers
Pires, M. M., Emmert, D., Hrycyna, C., & Chmielewski, J. (2009) · Molecular Pharmacology · doi:10.1124/mol.108.050492 · Cited by 102
“Previous studies have established that a broad-based drug resistance arises in large part from the overexpression of a plasma membrane polypeptide known as P-glycoprotein (P-gp) (Gottesman et al., 2002; Schinkel and Jonker, 2003; Löscher and Potschka, 2005).”
BackgroundHIV-1 Protease Inhibitor, Ritonavir
Ikezoe, T., Hisatake, Y., Takeuchi, T., Ohtsuki, Y., Yang, Y., SAID, J. W., Taguchi, H., & Koeffler, H. P. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2677 · Cited by 112
Seebacher, N. A., Richardson, D. R., & Jansson, P. J. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.381 · Cited by 111
Tetrandrine and cancer – An overview on the molecular approach
Bhagya, N., & Chandrashekar, K. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.10.116 · Cited by 114
Surface-modified polymeric nanoparticles for drug delivery to cancer cells
Ahmed, A., Sarwar, S., Hu, Y., Munir, M. U., Nisar, M. F., Ikram, F., Asif, A., Rahman, S. U., Chaudhry, A. A., & Rehman, I. U. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1822321 · Cited by 122
Smart transformable nanomedicines for cancer therapy
Wang, Y., Li, S., Wang, X., Chen, Q., He, Z., Luo, C., & Sun, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120737 · Cited by 112
New Advances in the Research of Resistance to Neoadjuvant Chemotherapy in Breast Cancer
An, J., Peng, C. Y., Tang, H., Liu, X., & Peng, F. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179644 · Cited by 125
“Current studies have found that exosomes can transmit miRNA and proteins between breast cancer cells to produce drug resistance [108].”
BackgroundThe intracellular pharmacology of antiretroviral protease inhibitors
Ford, J., Khoo, S., & Back, D. J. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh487 · Cited by 121
Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate Cancer
Marín‐Aguilera, M., Codony‐Servat, J., Kalko, S. G., Fernández, P. L., Bermudo, R., Buxó, E., Ribal, M. J., Gascón, P., & Mellado, B. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0289 · Cited by 122
“ABCA13, ABCA8, and ABCC2, all from theABC (ATP-binding cassette) family of drug transporters, are significantly deregulated in DU145R cells; onlyABCC2was already known to be involved inmultidrug resistance (27).”
BackgroundTemozolomide competes for P-glycoprotein and contributes to chemoresistance in glioblastoma cells
Munoz, J. L., Walker, N. D., Scotto, K. W., & Rameshwar, P. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.013 · Cited by 110
Pharmacokinetic aspects and in vitro–in vivo correlation potential for lipid-based formulations
Kollipara, S., & Gandhi, R. (2014) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2014.09.001 · Cited by 122
Shang-Hsun, T., Chen, T.-M., Hsiao, H.-T., & Chen, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0116747 · Cited by 111
“The ability of cancer cells to become simultaneously resistant to different drugs—a trait known as multidrug resistance (MDR)—remains a significant impediment to successful chemotherapy [1, 2].”
BackgroundNovel Extracellular Vesicles Mediate an ABCG2-Dependent Anticancer Drug Sequestration and Resistance
Ifergan, I., Scheffer, G. L., & Assaraf, Y. G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2021 · Cited by 107
New Findings on Breast Cancer Stem Cells: A Review
Bozorgi, A., Khazaei, M., & Khazaei, M. R. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.4.303 · Cited by 119
“In addition to physiological functions, ABC transporters have been reported to be important in multidrug resistance (MDR) in various cancers [73].”
BackgroundThe role of CD44 in cancer chemoresistance: A concise review
Yaghobi, Z., Movassaghpour, A. A., Talebi, M., Shadbad, M. A., Hajiasgharzadeh, K., Pourvahdani, S., & Baradaran, B. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174147 · Cited by 116
Wang, K., Yan, J., Zhang, B., Song, J., Jia, P.-F., & Wang, R. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.12.027 · Cited by 110
“The multi-drug resistance phenomenon is often associated with the over-expression of the transporters that recognize and efficiently expel from the cells a broad range of structurally unrelated compounds [32].”
BackgroundCarotenoids reverse multidrug resistance in cancer cells by interfering with ABC-transporters
Eid, S. Y., El-Readi, M. Z., & Wink, M. (2012) · Phytomedicine · doi:10.1016/j.phymed.2012.05.010 · Cited by 110
Beretta, G. L., Benedetti, V., Cossa, G., Assaraf, Y. G., Bram, E. E., Gatti, L., Corna, E., Carenini, N., Colangelo, D., Howell, S. B., et al. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.12.002 · Cited by 122
Wang, K., Liao, J., Yang, X., Zhao, M., Chen, M., Yao, W., Tan, W., & Lan, X. (2014) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2014.07.022 · Cited by 109
“In addition, ATP is used as a substrate in signal transduction pathways by kinases that phosphorylate proteins and lipids, as well as by adenylate cyclase, which uses ATP to produce the second messenger molecule cyclic AMP (Gottesman et al., 2002; Hardie and Hawley, 2001; Short et al., 1986).”
BackgroundThe Network of Non-coding RNAs in Cancer Drug Resistance
Corrà, F., Agnoletto, C., Minotti, L., Baldassari, F., & Volinia, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00327 · Cited by 111
“The acquisition of resistance to several types of anticancer drugs can be due to the expression of transporters that eject drugs from cells, resulting in multidrug resistance (3).”
BackgroundLiu, H., Chen, D., Li, L., Liu, T., Tan, L., Wu, X., & Tang, F. (2010) · Angewandte Chemie · doi:10.1002/ange.201002820 · Cited by 109
Mutational Analysis of ABCG2: Role of the GXXXG Motif
Polgár, O., Robey, R. W., Morisaki, K., Dean, M. C., Michejda, C. J., Sauna, Z. E., Ambudkar, S. V., Tarasova, N. I., & Bates, S. E. (2004) · Biochemistry · doi:10.1021/bi0497953 · Cited by 118
Self-citationMagnetic nanoparticles for cancer therapy
Dürr, S., Janko, C., Lyer, S., Tripal, P., Schwarz, M. A., Zaloga, J., Tietze, R., & Alexiou, C. (2013) · Nanotechnology Reviews · doi:10.1515/ntrev-2013-0011 · Cited by 109
“They are responsible for the simultaneous resistance to several different chemotherapeutic agents (multidrug resistance), as they transport these toxic substances out of the cells [84] .”
Sauna, Z. E., Kim, I.-W., Nandigama, K., Kopp, S., Chiba, P., & Ambudkar, S. V. (2007) · Biochemistry · doi:10.1021/bi701385t · Cited by 101
Masui, K., Gini, B., Wykosky, J., Zanca, C., Mischel, P. S., Furnari, F. B., & Cavenee, W. K. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt086 · Cited by 129
Role of pharmacogenetics in irinotecan therapy
de Jong, F. A., de Jonge, M. J. A., Verweij, J., & Mathijssen, R. H. J. (2005) · Cancer Letters · doi:10.1016/j.canlet.2005.04.040 · Cited by 125
“Besides influencing the renal and hepatobiliary secretion, these drug-pumps can affect intestinal reabsorption, and can also play a role in acquired (multi)drug resistance [18,42–44].”
BackgroundControlled release of free doxorubicin from peptide–drug conjugates by drug loading
Chen, Z., Zhang, P., Cheetham, A. G., Moon, J. H., Moxley, J. W., Lin, Y., & Cui, H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.051 · Cited by 109
Zhou, B., Sun, C., Li, N., Shan, W., Lü, H., Guo, L., Guo, E., Xia, M., WENG, D., Li, M., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3442 · Cited by 114
Alves, A. C., Magarkar, A., Horta, M., Lima, J. L. F. C., Bunker, A., Nunes, C., & Reis, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-06445-z · Cited by 108
Rising horizon in circumventing multidrug resistance in chemotherapy with nanotechnology
Choudhury, H., Pandey, M., Yin, T. H., Kaur, T., Jia, G. W., Tan, S. Q. L., Weijie, H., Yang, E. K. S., Keat, C. G., Bhattamisra, S. K., et al. (2019) · Materials Science and Engineering C · doi:10.1016/j.msec.2019.04.005 · Cited by 108
Reversal of breast cancer resistance protein–mediated drug resistance by tryprostatin A
Woehlecke, H., Osada, H., Herrmann, A., & Lage, H. (2003) · International Journal of Cancer · doi:10.1002/ijc.11444 · Cited by 108
Seo, S., Hatano, E., Higashi, T., Nakajima, A., Nakamoto, Y., Tada, M., Tamaki, N., Iwaisako, K., Mori, A., Doi, R., et al. (2008) · Surgery · doi:10.1016/j.surg.2008.01.010 · Cited by 112
Walker, J., Martin, C., & Callaghan, R. (2003) · European Journal of Cancer · doi:10.1016/j.ejca.2003.09.036 · Cited by 108
“[5–11]).”
BackgroundXu, K., Liang, X., Cui, D., Wu, Y., Shi, W., & Liu, J. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.21832 · Cited by 111
“to a single chemotherapy drug [3] and is the leading cause of cancer-related death.”
BackgroundNovel immune check point inhibiting antibodies in cancer therapy—Opportunities and challenges
Diesendruck, Y., & Benhar, I. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.001 · Cited by 114
Ma, H., Yang, M., Zhang, C., Ma, Y., Qin, Y., Lei, Z., Lu, C., Lei, L., Wang, T., & Yang, Y. (2017) · Journal of Materials Chemistry B · doi:10.1039/c7tb02399e · Cited by 107
Zhang, D., Ding, L., Li, Y., Ren, J., Shi, G., Wang, Y., Zhao, S., Ni, Y., & Hou, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-13431-y · Cited by 118
Adamska, A., & Falasca, M. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i29.3222 · Cited by 111
Albumin-based delivery systems: Recent advances, challenges, and opportunities
Murphy, G., Brayden, D. J., Cheung, D. L., Liew, A., Fitzgerald, M. T., & Pandit, A. S. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.01.035 · Cited by 119
Tryptanthrin inhibits MDR1 and reverses doxorubicin resistance in breast cancer cells
Yu, S.-T., Chen, T.-M., Tseng, S.-Y., & Chen, Y. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.04.107 · Cited by 117
Shukla, S., Robey, R. W., Bates, S. E., & Ambudkar, S. V. (2006) · Biochemistry · doi:10.1021/bi060552f · Cited by 103
Self-citationHauswald, S., Duque‐Afonso, J., Wagner, M. M., Schertl, F. M., Lübbert, M., Peschel, C., Keller, U. B., & Licht, T. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2048 · Cited by 107
Enaminones: Exploring Additional Therapeutic Activities
Edafiogho, I. O., Kombian, S. B., Ananthalakshmi, K. V. V., Salama, N. N., Eddington, N. D., Wilson, T. L., Alexander, M. S., Jackson, P. L., Hanson, C. D., & Scott, K. R. (2007) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.20967 · Cited by 120
Chearwae, W., Wu, C., Chu, H., Lee, T. R., Ambudkar, S. V., & Limtrakul, P. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0052-1 · Cited by 114
“One of the major mechanisms of Multidrug resistance (MDR) is the enhanced ability of tumor cells to actively efflux drugs leading to a decrease in cellular drug accumulation below toxic levels [13].”
BackgroundABC transporter expression in hematopoietic stem cells and the role in AML drug resistance
de Jonge-Peeters, S. D. P. W. M., Kuipers, F., de Vries, E. G. E., & Vellenga, E. (2007) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.02.003 · Cited by 120
“Cells xposed to toxic agents can develop resistance by a number of echanisms including decreased uptake, accelerated detoxfication, defective apoptosis pathways, alteration of target roteins, or increased efflux which lowers the effective drug oncentration inside the cell [81,94].”
BackgroundRole of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells
Han, C.-Y., Cho, K. B., Choi, H., Han, D., & Kang, K.-W. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn092 · Cited by 118
Tumor Microenvironment Promotes Cancer Progression, Metastasis, and Therapeutic Resistance
Sung, S., Hsieh, C., Wu, D., Chung, L. W. K., & Johnstone, P. A. S. (2007) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2006.12.002 · Cited by 123
Fan, S., Niu, Y., Tan, N. S., Wu, Z., Wang, Y., You, H. S., Ke, R., Song, J., Shen, Q., Wang, W., et al. (2012) · Oncogene · doi:10.1038/onc.2012.183 · Cited by 112
Sosnik, A. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.002 · Cited by 111
“According to their sequence and homology, they are classified into seven subfamilies named from A to G [2].”
BackgroundOvercoming Drug Resistance by Targeting Cancer Bioenergetics with an Activatable Prodrug
Sharma, A. K., Lee, M. G., Shi, H., Won, M., Arambula, J. F., Sessler, J. L., Lee, J. Y., Chi, S., & Kim, J. S. (2018) · Chem · doi:10.1016/j.chempr.2018.08.002 · Cited by 108
Ji, N., Yang, Y., Cai, C., Lei, Z., Wang, J., Gupta, P., Shukla, S., Ambudkar, S. V., Kong, D., & Chen, Z. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.10.007 · Cited by 111
“However, one important mechanism of MDR is mediated by the efflux pump protein, known as the ATP-binding cassette (ABC) transporters, which are located on the membrane of cancer cells [3,4].”
BackgroundDrug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines
Tepsiri, N. (2005) · World Journal of Gastroenterology · doi:10.3748/wjg.v11.i18.2748 · Cited by 106
“multidrug resistance protein [MDR1] and multidrug resistance-associated proteins [MRPs][ 17 ]), an increase in detoxification of chemotherapeutic drugs (e.g.”
BackgroundShort interfering RNA (siRNA): tool or therapeutic?
Cejka, D., Losert, D., & Wacheck, V. (2005) · Clinical Science · doi:10.1042/cs20050162 · Cited by 120
Safa, A. (2004) · Current Medicinal Chemistry-Anti-Cancer Agents · doi:10.2174/1568011043482142 · Cited by 105
Shen, D., Zhang, W., Zeng, X., & Liu, C. (2013) · Cancer Science · doi:10.1111/cas.12223 · Cited by 105
The role of P-glycoprotein in drug resistance in multiple myeloma
Abraham, J., Salama, N. N., & Azab, A. K. (2014) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2014.907890 · Cited by 113
ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
W. Robey, R., R. Massey, P., Amiri-Kordestani, L., & E. Bates, S. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794473957 · Cited by 85
“High endogenous levels of Pgp are found in the placenta, kidney, liver, brain microvasculature and gastrointestinal tract [1, 2].”
BackgroundInfluentialSelf-citationThe role of glucuronidation in drug resistance
Mazerska, Z., Mróz, A., Pawłowska, M., & Augustin, E. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.01.009 · Cited by 107
Mechanism of Action of ABC Importers: Conservation, Divergence, and Physiological Adaptations
Lewinson, O., & Livnat‐Levanon, N. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.01.010 · Cited by 114
Application of Nanoparticles and Nanomaterials in Thermal Ablation Therapy of Cancer
Ashikbayeva, Z., Tosi, D., Balmassov, D., Schena, E., Saccomandi, P., & Inglezakis, V. J. (2019) · Nanomaterials · doi:10.3390/nano9091195 · Cited by 113
“chemotherapeutic agents, causing additional obstacles for the treatment [4].”
BackgroundAlmatroudi, A., Khadri, H., Azam, M., Rahmani, A. H., Khaleefah, F. A., Khateef, R., Ansari, M. A., & Allemailem, K. S. (2020) · Processes · doi:10.3390/pr8040388 · Cited by 105
“In spite of various attempts, chemotherapy of cancerous cells is not fully successful due to multi drug resistance [14].”
BackgroundCancer Stem Cells as a Potential Target to Overcome Multidrug Resistance
Cho, Y., & Kim, Y. K. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00764 · Cited by 107
Hawthorne, D. J., & Dively, G. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026796 · Cited by 105
“The membrane-bound transporter proteins from the ABC transporter family of proteins are found in all phyla [14,15].”
BackgroundConjugating Berberine to a Multidrug Resistance Pump Inhibitor Creates an Effective Antimicrobial
Ball, A. R., Casadei, G., Samosorn, S., Bremner, J. B., Ausubel, F. M., Moy, T. I., & Lewis, K. (2006) · ACS Chemical Biology · doi:10.1021/cb600238x · Cited by 120
“Overexpression of P-glycoprotein plays an important role in tumor resistance to chemotherapeutic agents ( 10 ).”
BackgroundAdar, Y., Stark, M., Bram, E. E., Nowak-Sliwinska, P. M., van den Bergh, H., Szewczyk, G. M., Sarna, T., Składanowski, A., Griffioen, A. W., & Assaraf, Y. G. (2012) · Cell Death and Disease · doi:10.1038/cddis.2012.30 · Cited by 112
Filipits, M., Pohl, G., Rudas, M., Dietze, O., Lax, S., Grill, R., Pirker, R., Zielinski, C. C., Hausmaninger, H., Kubista, E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.033 · Cited by 104
Versatile RNA Interference Nanoplatform for Systemic Delivery of RNAs
Choi, K. Y., Silvestre, O. F., Huang, X., Min, K. H., Howard, G. P., Hida, N., Jin, A. J., Carvajal, N., Lee, S. W., Hong, J.-I., et al. (2014) · ACS Nano · doi:10.1021/nn500085k · Cited by 104
“known to be ascribed to multidrug resistance traits of various cancer cells.(30) We complexed MDR1-target”
BackgroundGou, P., Liu, W., Mao, W., Tang, J., Shen, Y., & Sui, M. (2012) · Journal of Materials Chemistry B · doi:10.1039/c2tb00004k · Cited by 105
p53 Maintains Genomic Stability by Preventing Interference between Transcription and Replication
Yeo, C. Q. X., Alexander, I., Lin, Z., Lim, S., Aning, O. A., Kumar, R., Sangthongpitag, K., Pendharkar, V., Ho, V. H. B., & Cheok, C. F. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.03.011 · Cited by 99
“…complex integration of various other factors that may influence drug response including, for example, gain of MDR (multi-drug resistance genes) (Gottesman et al., 2002), altered homologous recombination efficiency (Treszezamsky et al., 2007), decreased repair of TOP2-DNA cleavage adducts…”
BackgroundPolymeric Nanoparticles for the Treatment of Malignant Gliomas
Mahmoud, B. S., Alamri, A. H., & McConville, C. (2020) · Cancers · doi:10.3390/cancers12010175 · Cited by 110
“Such transporter is present in several organs such as brain, liver and placenta, for example and it functions by protecting organs from toxins [207].”
BackgroundProgress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK)
Lu, Y., & Sun, H. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01248 · Cited by 107
Kaurav, M., Ruhi, S., Al-Goshae, H. A. A., Jeppu, A. K., Ramachandran, D., Sahu, R. K., Sarkar, A. K., Khan, J., & Ikbal, A. M. A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1159131 · Cited by 112
“On the other hand, the EPR effect does not occur in a number of malignant tumours that are resistant to radiation because these cancers are impermeable (Gottesman et al., 2002).”
Background
Metadata
- Authors
- Gottesman, M. M., Fojo, T., & Bates, S. E.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Fojo, Tito
- Venue
- Nature Reviews Cancer
- Published
- 2002-01-01
- Volume
- 2
- Issue
- 1
- Pages
- 48-58
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2006434892
- Cited by
- 5,536
- References
- 168
- Citations by year
- 2026: 144 · 2025: 173 · 2024: 183 · 2023: 228 · 2022: 231 · 2021: 257 · 2020: 305 · 2019: 281 · 2018: 318 · 2017: 322 · 2016: 329 · 2015: 333 · 2014: 326 · 2013: 296 · 2012: 274
- FWCI
- 14.32
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Health Sciences › Medicine › Microbiology (medical) › Antibiotic Resistance in Bacteria
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › ATP Synthase and ATPases Research
- Keywords
- multidrug resistance, drug efflux pumps, chemoresistance, cancer chemotherapy, drug resistance mechanisms, metastatic cancer
- MeSH terms
- Adenosine Triphosphate, Antineoplastic Agents, Breast Neoplasms, Female, Forecasting, Multigene Family, Humans, Leukemia, Neoplasm Proteins, Neoplasms, Organ Specificity, Permeability, Structure-Activity Relationship, Drug Design, Xenobiotics, Biomarkers, Drug Resistance, Multiple, ATP-Binding Cassette Transporters, Drug Resistance, Neoplasm, ATP Binding Cassette Transporter, Subfamily B, Member 1, ATP-Binding Cassette, Sub-Family C Proteins, Multidrug Resistance-Associated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.